NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the peer-reviewed publication in Annals of Oncology* of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results